Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02451566
Other study ID # 771-0017
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2015
Est. completion date December 2016

Study information

Verified date June 2021
Source Endologix
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The primary objectives of the LIFE Study are to demonstrate the clinical cost and benefits associated with using the Ovation Prime Abdominal Stent Graft System under the least invasive conditions defined in the Fast-Track EVAR protocol. The key elements of the Fast-Track EVAR protocol include: appropriate patient selection, bilateral percutaneous access, no general anesthesia, no ICU admission post procedure, and next day discharge.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient is = 18 years of age. 2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study). 3. Patient has signed a Research Ethics Board (REB) approved Informed Consent Form. 4. Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification; refer to Appendix III: ASA Classification System). 5. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following: - Abdominal aortic aneurysm >5cm in diameter - Aneurysm has increased in size by 0.5cm in last 6 months - Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment 6. Patient has suitable anatomy that allows use of the TriVascular Ovation/Ovation Prime Abdominal Stent Graft System: - Iliac or femoral arteries that allow endovascular access with the TriVascular Ovation/Ovation Prime Abdominal Stent Graft System (14F OD). - Proximal aortic neck landing zone with an inner wall diameter of no less than 16 mm and no greater than 30 mm at 13 mm below the inferior renal artery. - Proximal aortic neck with a length of at least 7 mm proximal to the aneurysm - Distal iliac artery landing zone an inner wall diameter of no less than 8 mm and no greater than 20 mm. - Distal iliac artery landing zone an inner wall diameter of no less than 8 mm and no greater than 20 mm. - Distance from the most distal renal artery to most superior internal iliac artery measurement is at least 130 mm. 7. Patient has suitable femoral arteries at the percutaneous access site that allow use of the Perclose ProGlide Suture-Mediated Closure (SMC) System via the pre-close technique, including: - =5 mm in diameter - At least 2 cm segment for access, 10 mm above the origin of the profunda femoris branch and 10 mm below the lower margin of the inferior epigastric artery as determined on preoperative contrast-enhanced CT, angiography, or ultrasound. - No calcification on the anterior wall or circumferential (>50%) calcification on the posterior wall. - No prior groin incision, hematoma, or significant scarring. - No prior clip or collagen based vascular closure device placement within 90 days of procedure. - No prior femoral artery needle puncture within 30 days of procedure. - No current active localized groin infection, traumatic vascular injury, femoral artery aneurysm, arteriovenous (AV( fistula, or pseudoaneurysm. 8. Patient must be willing to comply with all required follow-up exams. Exclusion Criteria: 1. Patient has a need for emergent surgery. 2. Patient has a dissecting aneurysm. 3. Patient has an acutely ruptured aneurysm. 4. Patient has an acute vascular injury. 5. Patient has had a previous repair of the abdominal aortic aneurysm or the iliac artery. 6. Patient has a mycotic aneurysm or has an active systemic infection. 7. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina). 8. Patient has unstable peripheral artery disease with critical limb ischemia (CLI). 9. Patient has congestive heart failure (CHF). Subjects in Class I or II will be allowed to participate in the protocol, subjects in Class III or IV should be excluded. The New York Heart Association NYHA Functional Classification is used as a reference, see Appendix III. 10. Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 3 months. 11. Patient requires use of techniques (e.g. Chimney graft) that would cover the renal arteries. 12. Patient requires planned adjunctive devices (e.g. renal stents) to complete the procedure. 13. Patient has a major surgical or interventional procedure planned during or within ± 30 days of the AAA repair. 14. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome). 15. Patient has history of bleeding disorders or refuses blood transfusions. 16. Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0mg/dl. 17. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment. 18. Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG- based polymers, fluorinated ethylene propylene (FEP) or nitinol. 19. Patient is on home oxygen. 20. Patient is morbidly obese (BMI = 40 kg/m2). 21. Patient was admitted from a skilled nursing facility. 22. Patient has a limited life expectancy of less than 1 year. 23. Patient has an inability to be discharged within 1 day (one midnight stay) of the procedure. Examples included but are not limited to, comorbid conditions, unable to admit the day of procedure, live too far away from treatment center, or insufficient post-operative family support. 24. Patient is currently participating in an investigational device or drug clinical trial. 25. Patient has other medical social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Study Design


Intervention

Device:
Ovation Prime Abdominal Stent Graft System


Locations

Country Name City State
Canada St. Boniface General Hospital Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
TriVascular, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major Adverse Events 30 days
Secondary Serious and Non-Serious Adverse Events, including vascular and major access site vascular complications 30 days
Secondary Access Technical Success, defined as percent of procedures successfully completed with bilateral percutaneous access 30 days
Secondary Treatment Success, defined as percent of subjects who successfully follow least invasive protocol through discharge 30 days
Secondary Blood loss, including if transfusion required 30 days
Secondary Percent of procedures completed without general anesthesia 30 days
Secondary Anesthesia Time 30 days
Secondary Procedure Time 30 days
Secondary Contrast Volume 30 days
Secondary Fluoroscopy Time 30 days
Secondary Time to hemostasis 30 days
Secondary Time to ambulation 30 days
Secondary Time to normal diet 30 days
Secondary Groin pain via Wong-Baker FACES Pain Rating Scale- a 10-point visual analog scale (0=none; 10= worst imaginable) 30 days
Secondary Quality of Life via the EuroQol Group's EQ-5D form 30 days
Secondary Percent of subjects discharged without ICU admission 30 days
Secondary Length of ICU Stay, if required 30 days
Secondary Length of hospital stay 30 days
Secondary Percent of subjects discharged within only one midnight stay 30 days
Secondary Freedom from Type I and III endoleaks 30 days
Secondary Freedom from AAA rupture 30 days
Secondary Freedom from conversion to open repair 30 days
Secondary Freedom from AAA related secondary interventions 30 days
Secondary Freedom from mortality 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers

External Links